Switch theme
Sign up to access all valuation multiples
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China.
2009
583
LTM Revenue $118M
LTM EBITDA -$62.7M
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ascentage Pharma has a last 12-month revenue of $118M and a last 12-month EBITDA of -$62.7M.
In the most recent fiscal year, Ascentage Pharma achieved revenue of $222M and an EBITDA of -$744M.
Ascentage Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ascentage Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $210M | $222M | XXX | XXX | XXX |
| Gross Profit | $24.6M | $188M | XXX | XXX | XXX |
| Gross Margin | 12% | 85% | XXX | XXX | XXX |
| EBITDA | -$771M | -$744M | XXX | XXX | XXX |
| EBITDA Margin | -368% | -335% | XXX | XXX | XXX |
| Net Profit | -$782M | -$883M | XXX | XXX | XXX |
| Net Margin | -373% | -398% | XXX | XXX | XXX |
| Net Debt | n/a | $300M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Ascentage Pharma's stock price is $20.
Ascentage Pharma has current market cap of $1.7B, and EV of $1.8B.
See Ascentage Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.8B | $1.7B | XXX | XXX | XXX | XXX | $-0.97 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Ascentage Pharma has market cap of $1.7B and EV of $1.8B.
Ascentage Pharma's trades at 15.1x LTM EV/Revenue multiple, and -28.4x LTM EBITDA.
Analysts estimate Ascentage Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Ascentage Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.8B | XXX | XXX | XXX |
| EV/Revenue | 8.0x | XXX | XXX | XXX |
| EV/EBITDA | -2.4x | XXX | XXX | XXX |
| P/E | -1.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAscentage Pharma's NTM/LTM revenue growth is 26%
Ascentage Pharma's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $1.8M for the same period.
Over next 12 months, Ascentage Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Ascentage Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Ascentage Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -335% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -4% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -309% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 88% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 82% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 318% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 479% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ascentage Pharma acquired XXX companies to date.
Last acquisition by Ascentage Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Ascentage Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Ascentage Pharma founded? | Ascentage Pharma was founded in 2009. |
| Where is Ascentage Pharma headquartered? | Ascentage Pharma is headquartered in United States of America. |
| How many employees does Ascentage Pharma have? | As of today, Ascentage Pharma has 583 employees. |
| Who is the CEO of Ascentage Pharma? | Ascentage Pharma's CEO is Dr. Dajun Yang, M.D.,PhD. |
| Is Ascentage Pharma publicy listed? | Yes, Ascentage Pharma is a public company listed on NAS. |
| What is the stock symbol of Ascentage Pharma? | Ascentage Pharma trades under AAPG ticker. |
| When did Ascentage Pharma go public? | Ascentage Pharma went public in 2025. |
| Who are competitors of Ascentage Pharma? | Similar companies to Ascentage Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Ascentage Pharma? | Ascentage Pharma's current market cap is $1.7B |
| What is the current revenue of Ascentage Pharma? | Ascentage Pharma's last 12-month revenue is $118M. |
| What is the current EBITDA of Ascentage Pharma? | Ascentage Pharma's last 12-month EBITDA is -$62.7M. |
| What is the current EV/Revenue multiple of Ascentage Pharma? | Current revenue multiple of Ascentage Pharma is 15.1x. |
| What is the current EV/EBITDA multiple of Ascentage Pharma? | Current EBITDA multiple of Ascentage Pharma is -28.4x. |
| What is the current revenue growth of Ascentage Pharma? | Ascentage Pharma revenue growth between 2023 and 2024 was 6%. |
| Is Ascentage Pharma profitable? | Yes, Ascentage Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
